Related Experiment Video

Updated: Nov 5, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.9K

Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer

Yanan Liu1,2, Canwei Wang1, Jifa Li1

  • 1Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China.

Frontiers in Pharmacology
|May 13, 2021
PubMed

Insights

Fibroblast growth factor receptor 4 (FGFR4) drives cancer through abnormal signaling. Targeting FGFR4 offers a promising strategy for developing new cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase receptor implicated in various cancers.
  • Overexpression of FGFR4 and its ligand, FGF19, is frequently observed in numerous cancer types.
  • Aberrant FGFR4 signaling contributes to oncogenesis, making it a significant therapeutic target.

Purpose of the Study:

  • To review the diverse mechanisms of oncogenic activation of FGFR4.
  • To highlight current therapeutic strategies and inhibitors targeting FGFR4 for cancer treatment.

Main Methods:

  • Literature review of scientific publications on FGFR4.
  • Analysis of oncogenic mechanisms involving FGFR4.
  • Compilation of data on existing FGFR4 inhibitors.

Main Results:

  • FGFR4 activation involves complex signaling pathways contributing to cancer progression.
  • Several classes of FGFR4 inhibitors are under investigation and development.
  • These inhibitors show potential in preclinical and clinical settings for various cancers.

Conclusions:

  • FGFR4 is a critical mediator of oncogenic signaling in multiple cancers.
  • Targeting FGFR4 represents a promising therapeutic avenue for cancer treatment.
  • Further research into FGFR4 inhibitors is warranted to optimize cancer therapy.
Keywords:
FGF19FGFR4activatorcancerinhibitor

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.1K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K